Key result
Statin use during immune checkpoint inhibitor therapy is not associated with reduced ACS or mortality.
Why the study?
Immune checkpoint inhibitors (ICI) are associated with cardiotoxicity, and whether cardiovascular risk-reducing medications like statins can safely or should be used in cancer patients receiving ICI is not well-defined.
Does statin therapy reduce acute coronary syndrome and all-cause mortality without increasing ICI-associated myositis or hepatitis in cancer patients receiving immune checkpoint inhibitors?
Cohort (n=5,796)
Does statin therapy reduce acute coronary syndrome and all-cause mortality without increasing ICI-associated myositis or hepatitis in cancer patients receiving immune checkpoint inhibitors?
Answers are grounded in this paper and cite their sources.
In cancer patients receiving immune checkpoint inhibitors, guideline-indicated statin therapy is significantly underutilized (46% untreated) and, while safe regarding ICI-associated myositis and hepatitis, was not associated with reduced acute coronary syndrome or all-cause mortality.
Background Immune checkpoint inhibitors (ICI) are an expanding class of cancer therapies that have been associated with cardiotoxicity. Whether cardiovascular risk-reducing medications like statins can safely or should be used in patients with cancer receiving ICI is not well-defined. Methods In a retrospective cohort study of 5796 cancer patients receiving ICI (2015–2024), we identified statin use via prescription data and determined statin indications based on American College of Cardiology/American Heart Association (ACC/AHA) guidelines. We conducted chart review to investigate statin discontinuation and the incidence of ICI-associated myositis and hepatitis. We used multivariable Cox proportional hazards models and landmark analysis to assess the associations between statin use and outcomes including acute coronary syndrome (ACS) and all-cause mortality. Results Despite statin indications at ICI initiation, 937/2058 (46%) were untreated with statins. These untreated patients were more likely to be younger, of Hispanic/Latino ethnicity, have a higher Area Deprivation Index, and have diabetes mellitus, compared to patients on statins ( n = 1121). Rates of ICI-associated myositis and hepatitis were not statistically different between the statin-treated and statin-indicated groups ( p = 0.53 and 0.43, respectively). In the multivariable Cox proportional hazards models, statin use during ICI therapy had no statistically significant association with ACS (HR 1.13, CI 0.67–1.90), or death after 270 days of ICI initiation (HR 0.78, CI 0.55–1.09) in the secondary landmark analysis. Conclusion Nearly half of the patients receiving ICI with ACC/AHA statin indications were not on statin therapy, revealing significant underutilization. Statin therapy was not associated with an increased risk of ICI-associated myositis or hepatitis but was also not associated with improved cardiovascular or mortality outcomes in our study. Further studies are needed to investigate the safety and clinical outcomes of statins in patients on ICI.
No takes yet. Share an insight, caveat, or question.
Sheng et al. (2026) conducted a cohort in Cancer treated with immune checkpoint inhibitors (n=5,796). Statin therapy vs. No statin therapy (statin-indicated untreated) was evaluated on Acute coronary syndrome (ACS) (HR 1.13, 95% CI 0.67-1.90). Statin use during immune checkpoint inhibitor therapy was not associated with acute coronary syndrome or mortality after 270 days.
Synapse has enriched 10 related papers. Consider them for comparative context: